Recent description of a gonococcal strain with a TEM-135 β-lactamase that is considered to be an intermediate between the TEM-1 β-lactamase and an ESBL is frightening. [2] Adding to our distress is the emergence *Corresponding author (
of extensively drug resistant-NG (XDR-NG) in the last 3-4 years thereby making it a potential "superbug". As per the recent Centres for Disease Control and Prevention (CDC) report, due to the high consequence and significant risk associated with it, drug-resistant NG has been categorised under hazard level urgent. [3] We do not expect re-emergence of sensitivity to classical antibiotics in NG and its complex biology precludes vaccine development. We are at a point where appropriate alternatives to cephalosporins are not in sight. Therefore, efforts need to be directed toward the judicious use of resources. The recent sexually transmitted diseases treatment guidelines by CDC recommend increasing the dosage of ceftriaxone to 250 mg from 125 mg and inclusion of azithromycin 1 g. [4] This is in response to reports of increasing MICs. Similar approach was adopted in the past to combat creeping MICs to penicillin. There is also broadening of recommendations to include azithromycin, not only to provide co-treatment for other pathogens, e.g. Chlamydia trachomatis, but also possibly retard cephalosporin resistance development and dissemination. Evidence of benefit of combination therapy has been documented recently. However, there is a compelling need for strengthening and expanding the antimicrobial resistance (AMR) surveillance of NG to ensure that the recommended therapies are efficacious.
World Health Organisation has launched the global action plan to control the spread and impact of AMR in NG in 2012 with tenets combining broad-based control of drug resistance and public health control of gonorrhoea. [5] Research into, and identification of alternate treatment regimens are integral to the plan. However, in the absence of any new molecules, research is focussed on retooling the current armamentarium of antimicrobials. Among them, dual therapy comprising either gentamicin or gemifloxacin plus azithromycin has shown promising results.
There is a need to be vigilant as well as adopt newer technologies that can augment the existing culture-based surveillance approach for NG. Point-of-care tests for simultaneous detection of infection and the markers for resistance allowing real-time antimicrobial susceptibility testing will be invaluable for disease control.
Gonorrhoea is a significant public health problem with about 106 million cases occurring annually on a global basis. [1] It's causative agent, Neisseria gonorrhoeae (NG) (also known as the gonococcus) is a successful pathogen with a remarkable journey over the years. It has shown an exceptional ability to repeatedly develop resistance to the therapeutic agents used for its treatment in the last 7-8 decades. The evolution of resistance in NG is complex and may involve multiple mechanisms. The effectiveness of each of the agents-sulphanilamide, penicillin, tetracycline and fluoroquinolone, have had a limited life span. Currently, the extended spectrum cephalosporins (ESCs) recommended as first-line therapy for gonorrhoea will perhaps meet the same fate as its predecessors.
There is now a global documentation of decreasing susceptibility to ESCs over time, demonstrated by increasing minimum inhibitory concentrations (MICs) along with reports of therapeutic failure. This has not come as a surprise as gonococcus is known to possess a plastic genome. The events observed today mirror those observed during the emergence of penicillin resistance in the past. As a next step, can we now envisage the development of plasmid-mediated resistance too? Gonococcus harbours TEM-1 type β-lactamases. Mutations in TEM genes are not a rare event and happen due to selective antibiotic pressure. Ongoing usage of ESCs may lead to the evolution of extended-spectrum β-lactamase (ESBL) phenotype thereby abruptly ushering in the post-cephalosporin era.
